Alex Lu is a partner in the firm’s Intellectual Property Litigation practice. She is a dedicated advisor and advocate for clients across intellectual property and related commercial disputes, including patent infringement, trade secret, and licensing disputes. Alex has extensive experience in all phases of litigation, from pre-litigation counseling, preliminary injunction proceedings and early dispositive motions, bench and jury trials, and appeal. Alex has also litigated contractual disputes for clients across major international and US arbitral institutions, and is a member of the firm’s Life Sciences & Technology Arbitrations group.
Alex has devoted much of her practice to the ever-evolving landscape of IP considerations in the life sciences industry. She is a founding member and editor of the Big Molecule Watch, an award-winning blog reporting on legal and regulatory issues concerning biosimilars and biologics, and a contributing editor to Goodwin’s resource page on the Inflation Reduction Act & Medicare Pricing for Drugs and Biologics.
Alex’s work has earned her recognition by Benchmark Litigation (“40 & Under Hot List”) and Best Lawyers in America (“Ones to Watch,” 2024). Alex was also honored by the American Immigration Lawyers Association for her pro bono work as part of the Pereira Litigation Team (2019 Jack Wasserman Memorial Award for excellence in litigation in the field of immigration).
Experience
Representative matters include:
- Representing medical device innovator Insulet in a trade secret litigation against EOFlow. After a multi-week trial, the jury found in favor of Insulet and awarded damages of $452 million
- Representing a global biotech company in a high-stakes ICC arbitration initiated against a major global drug manufacturer relating to the parties’ product license and supply agreement
- Representing a public biopharmaceutical company in an arbitration involving a strategic collaboration and licensing agreement with a competitor following the launch of a new class of therapeutics
- Representing Dr. Reddy’s Laboratories in patent infringement litigation, including bench trials, preliminary injunction proceedings, IPRs, and appeals, concerning Dr. Reddy’s generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films
- Representing Teva in patent infringement litigation, including a jury trial and appeal, against GlaxoSmithKline concerning Teva’s generic version of Coreg® (carvedilol) tablets.
- Representing Celltrion and Teva in patent infringement litigation under the BPCIA, including preparations for a hearing on motion for a preliminary injunction, concerning Celltrion’s and Teva’s proposed biosimilar rituximab product
Alex is also committed to pro bono work. She has represented several unaccompanied minors seeking asylum and Special Immigrant Juvenile status in immigration court and in related state court proceedings. Alex was also part of a team that successfully won an immigration case before the Supreme Court concerning the interpretation of the stop-time rule for cancellation of removal.
Credentials
Education
JD2014
Yale Law School
AB2011
Harvard College
Admissions
Bars
- Massachusetts
Courts
- U.S. District Court for the District of Massachusetts
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Appeals for the Second Circuit
- U.S. Supreme Court
Recognition & Awards
- Benchmark Litigation - “40 & Under Hot List,” 2024
- Best Lawyers in America - “Ones to Watch,” 2024
- Recognized as part of the Pereira Litigation Team by American Immigration Lawyers Association, Jack Wasserman Memorial Award for excellence in litigation in the field of immigration, 2019
Publications & Presentations
- Speaker, “Updates on the Drug Price Negotiation Program of the Inflation Reduction Act: An Overview of Recent Court Decisions, the Status of Remaining Challenges, and the Status of ‘Negotiations,’” Goodwin webinar, 2024
- Speaker, “IP Year in Review: IP in Life Sciences,” Boston Bar Association IP Year in Review Conference, 2024
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” published by Thomson Reuters, 2024
- Speaker, “Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies,” Goodwin webinar, 2023
- Speaker, “Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al., Goodwin webinar, 2023
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, 2022
- Speaker, “BPCIA Patent Dance Disclosures: Discovery During the Patent Dance and Beyond,” Goodwin Webinar, 2020
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, 2019
- Co-Author, “KIND Pro Bono Attorney Spotlight,” 2018
- Speaker, “The Impact of Amgen v. Sandoz,” Goodwin webinar, 2015
- Co-Author, “Plants and Potions,” Intellectual Property Magazine, 2015
- Co-Author, “Order in Amgen v. Sandoz Provides First Judicial Interpretations of the BPCIA Patent Dispute Resolution Provisions,” 2015
- Media mention, “Goodwin Procter Launches Big Molecule Watch Blog for Biosimilars Industry,” 2015
- Media mention, “Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?,” Scrip, 2016
- Co-Author, “Dance Fever: A Recap of Recent BPCIA Litigation,” Bloomberg Law, 2017
- Co-Author, “Sanctuary Cities: Distinguishing Rhetoric From Reality,” Boston Bar Journal, 2017
- Co-Author, “Goodwin Trial Win Clears Patent Hurdle for Dr. Reddy’s Generic Suboxone®,” 2017
- Co-Author, “No Child Stands Alone,” 2017